Batlevi CL et al. Interim analysis of the randomized phase 1b/3 study evaluating the safety and efficacy of tazemetostat plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma. ASH 2021;Abstract 2207.
Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014;32(27):3059-68. Abstract
Jacobson CA et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23(1):91-103. Abstract
Lee DW et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25(4):625-38. Abstract
Leonard JP et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37(14):1188-99. Abstract
Morschhauser F et al. Glofitamab as monotherapy in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). ASH 2021;Abstract 128.
Morschhauser F et al. Interim update from the phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma. ICML 2019;Abstract 105.
Morschhauser F et al. Six-year results from the phase 3 randomized study relevance show similar outcomes for previously untreated follicular lymphoma patients receiving lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance. ASH 2021;Abstract 2417.
Morschhauser F et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21(11):1433-42. Abstract
Neelapu SS et al. Long-term follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-hodgkin lymphoma (iNHL). ASH 2021;Abstract 93.
Thieblemont C et al. Efficacy of tisagenlecleucel in adult patients (Pts) with high-risk relapsed/refractory follicular lymphoma (r/r FL): Subgroup analysis of the phase II elara study. ASH 2021;Abstract 131.
Townsend W et al. Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Final analysis of the GALLIUM study. EHA 2022;Abstract S206.